Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05932472 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Randomized Comparison of Morning Versus Bedtime Administration of Aspirin: A Cardiovascular Circadian Chronotherapy (C3) Trial

Study acronym: ASPIRIN-C3
StatusRecruiting
PhasePhase 4
Started
View on ClinicalTrials.gov ↗

Record History

  1. Trial status: Not Yet Recruiting to Recruitingv2 Show 4 more changesShow less
    • Start date changed from estimate of Aug 1, 2023 to Jan 15, 2024
    • Study sites: 0 to 1
    • Primary completion date: Aug 1, 2026 to Jan 15, 2027
    • Study completion date: Aug 1, 2026 to Feb 15, 2027
  2. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Wide variability in the antiplatelet effects of aspirin may lead to recurrent thromboembolic events. Several pilot studies have suggested potential benefits of taking aspirin at bedtime rather than in the morning. The primary objective of this study is to examine whether aspirin administration at bedtime versus in the morning provides a superior reduction in the incidence of major adverse cardiovascular events among patients with or without established atherosclerotic cardiovascular disease, who are already taking aspirin.
Trial Details
NCT Number NCT05932472
Lead Sponsor Tor Biering-Sørensen
Conditions
(from sponsor)		 Atherosclerosis, Cardiovascular Diseases, Drug Effect
Related terms Atherosclerosis, Cardiovascular Diseases
Enrollment 32,706 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov